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Abstract
Background: The naturally-acquired immune response to Plasmodium vivax variant antigens (VIR)
was evaluated in individuals exposed to malaria and living in different endemic areas for malaria in
the north of Brazil.
Methods: Seven recombinant proteins representing four vir subfamilies (A, B, C, and E) obtained
from a single patient from the Amazon Region were expressed in Escherichia coli as soluble
glutathione S-transferase fusion proteins. The different recombinant proteins were compared by
ELISA with regard to the recognition by IgM, IgG, and IgG subclass of antibodies from 200
individuals with patent infection.
Results: The frequency of individuals that presented antibodies anti-VIR (IgM plus IgG) during the
infection was 49%. The frequencies of individuals that presented IgM or IgG antibodies anti-VIR
were 29.6% or 26.0%, respectively. The prevalence of IgG antibodies against recombinant VIR
proteins was significantly lower than the prevalence of antibodies against the recombinant proteins
representing two surface antigens of merozoites of P. vivax: AMA-1 and MSP119 (57.0% and 90.5%,
respectively). The cellular immune response to VIR antigens was evaluated by in vitro proliferative
assays in mononuclear cells of the individuals recently exposed to P. vivax. No significant
proliferative response to these antigens was observed when comparing malaria-exposed to non-
exposed individuals.
Conclusion: This study provides evidence that there is a low frequency of individuals responding
to each VIR antigens in endemic areas of Brazil. This fact may explain the host susceptibility to new
episodes of the disease.
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Background
Plasmodium vivax is the second most prevalent malaria
species of world with an estimated 80–90 million cases a
year [1]. In Americas and Asia, P. vivax is the most preva-
lent malaria species, and in Brazil it represents more than
75% of the clinical cases reported annually [2].
Variant antigens exposed on P. vivax-infected reticulocytes
are encoded by a single multigene superfamily termed vir
(P. vivax variant genes), with circa 600–1,000 copies per
haploid genome [3]. Moreover, in silico analysis of vir
sequences from endemic regions have demonstrated that
sequences can be grouped into different subfamilies (A-E)
based on sequence similarities and structural properties
[4,5]. Furthermore, in silico, analysis has also revealed
that vir genes are part of the large pir superfamily (Plasmo-
dium interspersed repeat), conserved among different spe-
cies and whose members seem to play a major role in
antigenic variation [6]. Antigenic variation is a common
phenomenon in all species of Plasmodium this far studied,
including the species infecting rodents, monkeys and
humans (Plasmodium yoelii, Plasmodium berghei, Plasmo-
dium chabaudi, Plasmodium knowlesi, Plasmodium fragile
and Plasmodium falciparum) [7]. These Plasmodium species
apparently use antigenic variation to evade the immune
system and to maintain the parasite survival. In P. falci-
parum, variant antigens are implicated in cytoadherence to
the endothelium of venullar capillaries in the deep vascu-
lar of inner organs. The major role of vir genes and their
encoding variant proteins in natural infections is pres-
ently unknown, although recently it has been proposed
that they have a role in spleen-specific cytoadherence and
establishment of chronic infections [8].
Several lines of evidence support the idea that antibody
responses directed to P. falciparum clonally variant surface
antigens (VSA) contribute to the acquired immune protec-
tion against malaria caused by this protozoan parasite [9-
13]. The VSA described to date include P. falciparum eryth-
rocyte membrane protein 1 (PfEMP-1) [14] and the rifins
[15,16]. Unlike PfEMP1 proteins, VIR proteins are not
clonally expressed by individually infected reticulocytes
and very little information is available regarding the natu-
rally acquired immune response against these proteins
[4]. In order to determine whether VIR proteins are target
of naturally acquired immunity, the antibody response of
P. vivax infected patients in the Brazilian Amazon was
recently analysed using glutathione S-transferase fusion
proteins (GST-VIR) expressing exon II and representing
the various VIR subfamilies (A-E) from three patients [4].
The present study was designed to evaluate the prevalence
of IgM, IgG and IgG subclasses to VIR proteins as esti-
mated by ELISA in 200 individuals exposed to malaria
from the Amazon Region, Brazil. Seven soluble GST
fusion proteins corresponding to four VIR subfamilies (A,
B, C, and E) obtained from parasites of a single patient
from the Amazon Region were used in this study. The
serum recognition pattern of these individuals was com-
pared with their ability to recognize two recombinant pro-
teins representing two merozoite surface antigens of P.
vivax: the 19 kDa C-terminal region of the Merozoite Sur-
face Protein-1 (MSP119) and the apical membrane antigen
1 (AMA-1). Finally, the study was complemented by esti-
mating in vitro PBMC proliferative responses upon stim-
ulation with these recombinant proteins.
Methods
Subjects
After verbal consent, blood samples from 261 individuals
were collected. A total of 220 serum samples were used for
serological analysis. Two hundred samples were from
patients with patent P. vivax malaria and 20 from individ-
uals never exposed to malaria (negative controls). Blood
samples from P. vivax patients were collected in five differ-
ent malaria endemic regions in the State of Pará, north
Brazil: i) city of Belém (n = 64), ii) city of Itaituba (n = 20),
iii) city of Marabá (n = 21), iv) city of Tailândia (n = 20),
and v) city of Igarapé-Açu (n = 32). Other 43 blood sam-
ples were collected in the State of Rondônia, in the north
of Brazil. Patent infection was documented by micro-
scopic analysis of Giemsa-stained blood smears. The
mean age of this group was 28.3 ± 13.3 years old and
69.7% of the subjects were male. Clinical and laboratory
data have been reported elsewhere for all individuals
including individuals never exposed to malaria [4,17-19].
Only individuals, from whom precise information on the
number of P. vivax malaria episodes was available, were
used to establish a correlation between the number of
malarias and the frequency of responders to recombinant
proteins.
Fifteen to twenty ml of venous blood of 41 individuals
were collected aseptically in heparinized tubes and trans-
ported at room temperature, within 48 h, for lymphoblas-
tic proliferation assays. The first group of individuals was
one of healthy adult volunteers from the city of São Paulo,
State of São Paulo, in the southeast of Brazil. Malaria is
not present in this part of the country and these individu-
als had never had malaria or traveled to malaria-endemic
areas. The total number of volunteers was 14, their aver-
age age was 30.1 ± 6.6 years old and 50.0% of the subjects
were male. The second group was composed by 27 adults
from the area of Augusto Correa, State of Pará in the north
of Brazil, and they had been treated for P. vivax malaria in
the previous 3 months. The mean age of this group was
33.6 ± 15.0 years old and 44.4% of the subjects were male.
The Ethics Committee of the University of São Paulo had
approved this study.
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Recombinant proteins
VIR
Seven glutathione S-transferase fusion proteins corre-
sponding to four vir subfamilies (A, B, C, and E) obtained
from parasites of a single patient from the Amazon Region
were used in this study. The detailed construction has
been described elsewhere [4]. Recombinant Escherichia
coli BL21 (DE3) was grown at 37°C under constant shak-
ing in multiple flasks containing 500 ml of LB-ampicillin.
When the preparation reached an OD600 = 1.0, isopropyl-β-D thiogalactopyranoside (IPTG, Invitrogen, Auckland,
New Zealand) was added to a final concentration of 2
mM, except to VIR-C16, which was induced with 0.1 mM
IPTG. Cultures were incubated at 18°C under constant
shaking for 16 h and bacterial pellets were obtained by
centrifugation and resuspended in sonication buffer [10
mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 100 µg/
ml lysozyme and 0.05 volumes of the Protease Inhibitor
Cocktail (Sigma, Saint Louis, USA)]. Bacteria were lysed
on ice with the aid of a sonicator (Branson model 450,
Danbury, CT). Five sonication cycles, consisting of 30 sec-
onds pulses at 1 min interval, were applied. Bacterial
lysates were centrifuged at 3,000 g for 30 min at 4°C.
Recombinant proteins were purified from the supernatant
of the bacterial lysates using Glutathione Sepharose 4B
Fast Flow columns (Amersham Biosciences, Uppsala,
Sweden), and their purity determined by SDS-PAGE. As
control, GST was produced alone.
AMA-1
The recombinant protein His6-AMA-1 represents AA 43 to
487 of the P. vivax AMA-1. This protein was expressed in
E. coli and purified as previously described [19].
MSP119
The recombinant protein His6-MSP119 represents the 19
kDa C-terminal region of the MSP-1 (AA 1616–1704,
Belém strain). This protein was expressed in E. coli and
purified as previously described [20].
Immunoassays
Detection of antigen specific IgG antibodies by ELISA
Human IgG antibodies against VIR, AMA-1 and MSP119
were detected by ELISA as described [18,19], except that
the plates were coated with 100 ng/well of each protein.
The OD492 values to each recombinant VIR protein were
obtained by subtracting the OD492 values of the same
serum to GST alone. The results were expressed as Index of
Reactivity (IR = OD492 values of test sample divided by the
value of the cutoff). Cut-off points were set at three stand-
ard deviations above the mean OD492 of sera from 15
individuals, unexposed to malaria, from the city of São
Paulo. Values of IR ≥ 1.0 were considered as positive.
Determination of antigen-specific antibodies of distinct IgG and IgM 
subclasses by ELISA
ELISA was performed using subclass-specific mouse anti-
human IgG or anti-human IgM as the second-step reagent.
These mAbs recognize human IgG1, IgG2, IgG3 or IgG4 or
IgM (Sigma, Saint Louis, USA) and were diluted 1:3,000
(anti-IgG1), 1:1,000 (anti-IgG2 and anti-IgG3), 1:500
(anti-IgG4) or 1:10,000 (anti-IgM) in PBS-5% non-fat
milk. After 1 h incubation at room temperature, plates
were washed and peroxidase labeled anti-mouse heavy
and light chain IgG (Sigma, Saint Louis, USA) was added
to a final concentration of 1:5,000. Only serum samples
that had IgG specific for the recombinant protein VIR were
tested for IgG subclass. Each serum was tested in duplicate
and the OD492 values were averaged. Cut-off points were
calculated as described above.
Peripheral blood mononuclear cells (PBMC) proliferation 
assay
The proliferation assays were performed as described else-
where [21]. Blood samples were collected in heparinized
tubes and transported to the laboratory within 20 h. After
diluted with the same volume of PBS, PBMC were isolated
on Ficoll-Paque (Amersham Biosciences, Uppsala, Swe-
den) by centrifugation. The PBMC at the interface were
collected, washed three times in PBS, and ressuspended in
complete media. Viable PBMC counts were made under a
phase-contrast microscope by the trypan blue dye exclu-
sion test. The complete media was RPMI 1640 medium
(Invitrogen, Auckland, New Zealand) supplemented with
10% normal human serum, 2 mM L-glutamine, 10 mM
Hepes, 0.2% sodium bicarbonate, 5 × 10-5 M 2-mercap-
toethanol, 1 mM sodium pyruvate, 1 mM non-essential
amino acid solution, 100 U/ml penicilin and streptomy-
cin. A total of 2.0 × 105 cells in 200 µl of culture media
were added to each well of a flat bottom 96-well plate
(Corning Co., NY). Each recombinant protein VIR,
MSP119 or GST was added in 20 µl. The final concentra-
tion of recombinant proteins or GST was 2 and 10 µg/ml.
Because of the antigen limitation, only one recombinant
protein representing each subfamily VIR was used (A4,
B10, C1, and E5). The assay was performed in triplicate
cultures and one of these triplicates contained only cul-
ture medium. Concanavalin A (Sigma, Saint Louis, USA)
was used as positive control in all the experiments. Cul-
tures were incubated in a humid environment, at 37°C, in
a 5% CO2 atmosphere for 5 days. Subsequently, 25 µl of
complete medium containing 1 µCi of [3H]-thymidine
(Amersham Bioscences, Buckinghamshire, England) was
added to the cultures. After 20–24h, cultures were har-
vested with a semi-automatic cell harvester, and radioac-
tivity was determined in a liquid scintillation counter. The
arithmetic mean cpm for each set of triplicate wells was
calculated, and the stimulation indices (SI) were deter-
mined as the arithmetic mean cpm of recombinant pro-
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tein-stimulated culture divided by the arithmetic mean
cpm of the GST-stimulated culture to VIR proteins or
medium alone to recombinant protein MSP119. The back-
ground counts for GST varied from 264 to 2,126 cpm.
Statistical analysis
Differences between proportions of responders were ana-
lysed using the Chi-square test. Mann-Whitney test was
used to compare the median of the Index of Reactivity
(IR) among groups. The significance level was set at P <
0.05.
Results
Purification of recombinant VIR proteins
Previous studies by us failed to solubilized GST-VIR tags
[4]. In the present study, it was established that low
expression temperature (18°C) and high concentrations
of IPTG cooperatively improved the solubility of GST-VIR
recombinant proteins. Using this strategy, soluble anti-
gens were purified by GST affinity chromatography. Fig-
ure 1 shows the SDS-PAGE analysis of the purified
recombinant proteins performed under denaturing condi-
tions in the presence of the reducing agent 2-ME. Each
protein migrated with apparent molecular weights of 42
kDa (VIR-A4), 47 kDa (VIR-B10), 52 kDa (VIR-C1 and
VIR-C2), 54 kDa (VIR-C16), 59 kDa (VIR-E5 and VIR-E8).
Recognition of recombinant VIR proteins and two 
merozoite surface antigens of P. vivax (AMA-1 and 
MSP119) by antibodies of individuals with patent vivax 
malaria
Serum antibodies (IgM, IgG and IgG subclasses) from
individuals living in different endemic areas for malaria in
the north of Brazil were tested for recognition of VIR pro-
teins. Initially, 200 serum samples collected from individ-
uals with patent infection were tested by ELISA, using as
antigens seven GST-fusion proteins representing four VIR
subfamilies (A, B, C, and E). The results show that a total
of 49.0% of subjects presented antibodies (IgM plus IgG)
to at least one of the recombinant proteins representing
VIR antigens indicating that these proteins are immuno-
genic during natural human infections. The frequency of
individuals that presented IgG antibodies to at least one of
the recombinant proteins VIR was 26.0%. Table 1 shows
that the frequency of responders against each recom-
binant protein VIR ranged from 2.0% (protein VIR-C16)
to 17.5% (protein VIR-C2). None of the seven VIR pro-
teins tested was immunodominant. However, when the
prevalence of individuals that presented IgG antibodies to
each VIR subfamily was analysed, the prevalence of anti-
bodies against VIR-C subfamily was significantly higher
than the prevalence against other subfamilies (P < 0.05,
Chi-Square test). Recombinant proteins AMA-1 and
MSP119 were also used to compare the reactivity of serum
samples. The frequency of individuals with IgG antibodies
to AMA-1 and MSP119 was 57.0% and 90.5%, respectively
(Table 1).
The frequencies of individuals who responded to recom-
binant proteins VIR were significantly lower than the fre-
quency of responders to AMA-1 and MSP119 (P < 0.05,
Chi-Square test). When the IR values from individual
serum samples were compared, values obtained for both
Table 1: Prevalence of the antibody response in 200 individuals 
with patent Plasmodium vivax malaria
Number of positive sera (%)
Recombinant protein IgG IgM
VIR-A4 22 (11.0) 36 (18.1)
VIR-B10 22 (11.0) 18 (9.0)
VIR-C1 23 (11.5) 12 (6.0)
VIR-C2 35 (17.5) 22 (11.0)
VIR-C16 4 (2.0) 30 (15.1)
VIR-E5 20 (10.0) 26 (13.1)
VIR-E8 5 (2.5) 30 (15.1)
AMA-1 114 (57.0) ND
MSP119 181 (90.5) ND
The percentage of responders was calculated as described in the 
Methods section. Serum samples were tested at a dilution of 1:100. 
The cut-off values for each recombinant protein were: VIR-A4, 0.166; 
VIR-B10, 0.121; VIR-C1, 0.119; VIR-C2, 0.136; VIR-C16, 0.183; VIR-
E5, 0.116; VIR-E8, 0.251; AMA-1, 0.341; MSP119, 0.192 (for IgG). VIR-
A4, 0.165; VIR-B10, 0.099; VIR-C1, 0.204; VIR-C2, 0.190; VIR-C16, 
0.138; VIR-E5, 0.143; VIR-E8, 0.150 (for IgM)
SDS-PAGE analysis of the purified recombinant proteins cor-responding to the dif erent VIR subfamiliesFigure 1
SDS-PAGE analysis of the purified recombinant pro-
teins corresponding to the different VIR subfamilies. 
Bacterial recombinant VIR proteins were expressed and 
purified as described in the Methods section. Lanes, 1: 
Molecular mass marker; 2: GST; 3: VIR-A4; 4: VIR-B10; 5: 
VIR-C1; 6: VIR-C2; 7: VIR-C16; 8: VIR-E5; 9: VIR-E8.
   1     2     3     4      5     6     7      8      9
116 –
66
45
25 –
14 –
–
–
35 –
18 –
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were higher than those observed for VIR (data not shown,
P < 0.05, Mann-Whitney). A schematic diagram of the IgG
antibody response against recombinant VIR proteins, in
each individual with patent P. vivax malaria, is shown in
Additional File 1. In addition, the IgM prevalence against
each recombinant protein VIR was also evaluated. A total
of 29.6% of subjects recognized at least one of the recom-
binant proteins VIR. As can be seen in Table 1 the fre-
quency of responders against each recombinant protein
VIR ranged from 6.0% (protein VIR-C1) to 18.1% (pro-
tein VIR-A4).
Because the subclass of IgG produced in response to a
given antigen may determine the function of the anti-
body, the IgG subclasses were estimated by subclass-spe-
cific ELISA using as antigen recombinant proteins VIR. No
statistically difference was observed in IgG subclass distri-
bution of antibodies, except to VIR-C whose antibodies
are mainly IgG1 subclass (Table 2).
In order to determine whether there was a correlation
between the frequency of IgG antibodies and episodes of
P. vivax infection, the sera of the 186 individuals were sep-
arated according to the previous number of malaria epi-
sodes. Individuals were divided in three groups: i)
primary-infected, individuals with no previous malaria
episodes; ii) individuals with 1 or 2 previous malaria epi-
sodes; and iii) individuals with ≥ 3 previous malaria epi-
sodes. The frequency of responders to recombinant
proteins VIR did not increase according to the number of
previous P. vivax malaria episodes (Figure 2, P > 0.05, Chi-
Square test) which confirms recently obtained data [4]. In
contrast, the frequency of serum samples containing IgG
anti-AMA-1 was significantly higher in groups ii and iii,
that had previous malaria episodes when compared with
the group without previous malaria episodes (P < 0.05,
Chi-Square test). This result suggests that the infection
provides a boost to the production of antibodies specific
for the AMA-1 that is not observed in the case of the VIR
proteins. The frequency of individuals containing anti-
MSP119 IgG was high (85.6%) in the group without previ-
ous malaria episodes, confirming previous data showing
that antibody response against MSP119 was established
after a single exposure to malaria [18,19].
PBMC proliferative response after in vitro culture with 
different recombinant proteins VIR and MSP119
PBMC were collected from 27 individuals recently treated
for malaria infection. These cells were tested for prolifera-
tion upon culture in the presence of one representing of
each VIR subfamily (A4, B10, C1, and E5), GST or
MSP119. Recombinant proteins or GST were tested, in trip-
licates, at the two distinct final concentrations of 2 and 10
µg/ml. Individuals who showed SI > 2.5 for at least one of
the two concentrations of recombinant protein, when
compared to PBMC cultures containing the GST alone
(VIR) or medium alone (MSP119), were considered as
positive responders. The frequency of individuals who
responded to each recombinant protein was estimated. As
control, it was estimated the frequency of responders to
each recombinant protein among 14 healthy subjects res-
ident in the city of São Paulo, State of São Paulo, in the
southeast of Brazil. These individuals had never had
malaria or traveled to malaria-endemic areas.
The frequency of responders among individuals exposed
to malaria was low and ranged from 3.7% (VIR-A4 and
VIR-C1) to 7.4% (VIR-B10 and VIR-E5) (data not shown).
PBMC obtained from 85.2% of the individuals treated for
malaria failed to proliferate in response to any recom-
binant protein tested. The lack of response to recom-
binant proteins VIR and MSP119 in a large number of
individuals from endemic areas was not due to loss of via-
bility in culture, because cells from all individuals
responded vigorously to Con A (data not shown). None
of the individuals who had never been exposed to malaria
group was a responder. The proportions of responders
between the two groups of individuals were compared sta-
tistically. The frequency of responders to the all recom-
binant proteins was not statistically different between the
groups of malaria exposed and the unexposed individu-
als. The SI obtained after stimulation with each one of the
recombinant proteins VIR and MSP119 among individuals
exposed to malaria is presented in Fig. 3. As one can see,
the positive responders to VIR proteins had SIs between
2.6 and 4.5. No individual of the exposed group was
responder to MSP119.
Discussion
In the present study, the serum antibody and PBMC reac-
tivity of individuals exposed to P. vivax malaria with
Table 2: Frequency of malaria exposed individuals with 
antibodies of distinct IgG subclass specific for recombinant 
proteins VIR
% of positive sera
IgG VIR-A VIR-B VIR-C VIR-E
Subclass
IgG1 9.5 4.8 38.6 15.0
IgG2 14.3 0 13.6 20.0
IgG3 14.3 4.8 15.9 25.0
IgG4 14.3 0 11.4 0
The percentage of responders was calculated as described in the 
Methods section. The ELISA was performed using subclass-specific, 
anti-human IgG1, IgG2, IgG3 or IgG4 and serum samples at a dilution 
of 1:25. Only serum samples that had total IgG specific for proteins 
VIR were tested in this assay. The cut-off values were defined as the 
mean plus 3 standard deviation values obtained from 20 uninfected 
control sera.
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recombinant proteins representing P. vivax variant anti-
gens (VIR) have been characterized and compared. This
effort represents the first description of the antigenic prop-
erties of the VIR antigens expressed and purified as soluble
proteins from E. coli.
Initially, it was determined the frequency of individual
serum samples that contained IgM or IgG antibodies to
each of the seven recombinant proteins representing four
VIR subfamilies. The results show that a considerable pro-
portion of individuals recognized at least one of these
Association between the percentage of responders that recognize each recombinant protein and the number of previous epi-sodes malariaFigure 2
Association between the percentage of responders that recognize each recombinant protein and the number 
of previous episodes malaria. A total of 186 individuals were grouped according to the number of times they had episodes 
of P. vivax malaria. The cut-off values were the same as used for Table 1. There was a significant increase in the percentage of 
individuals containing IgG anti-AMA-1 in the groups with previous malaria episodes when compared with individuals without 
previous episodes of the disease (P < 0.05, Chi-Square test). No statistically significant difference was observed among the fre-
quencies of sera from individuals containing IgG antibodies anti-VIR and anti-MSP119 in the different groups of individuals (P > 
0.05, Chi-Square test).
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PBMC proliferative response to recombinant proteins VIR and MSP119 from individuals recently exposed to P. vivaxFigure 3
PBMC proliferative response to recombinant proteins VIR and MSP119 from individuals recently exposed to P. 
vivax malaria. PBMC proliferation assay was performed as described in the Methods section. Each recombinant protein VIR, 
MSP119 or GST was tested in final concentration of 2 and 10 µg/ml. Individuals were considered as positive responders when 
they showed SI > 2.5 for at least one of the two concentrations of recombinant protein when compared to PBMC cultures 
containing the GST protein alone (VIR proteins) or medium alone (MSP119). Symbols represent the SI obtained after stimula-
tion with each antigen at the final concentration of 2 µg/ml (A) or 10 µg/ml (B). The horizontal lines represent the SI = 2.5. 
Individuals never exposed to malaria did not respond to antigen stimulation (data not shown). PBMC were also stimulated with 
Con A as positive controls. The SI obtained after stimulation with this mitogen varied from 15 to 178.2 (data not shown).
B
A
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recombinant proteins (29.6% and 26.0% for IgM and
IgG, respectively), although the antibody levels (esti-
mated by the OD) were generally low. Considering the
high gene copy number per haploid genome [3] and high
polymorphism of the VIR proteins in natural parasite
populations [4,5], these results suggest that this protein
can be highly immunogenic during natural human infec-
tions.
Among the different VIR subfamilies, the VIR-C was most
frequently recognized by human IgG antibodies. The fact
that three recombinant proteins representing the sub-
family C (VIR-C1, VIR-C2, and VIR-C16) were used, may
explain the higher frequency of responders to this sub-
family. Moreover, the subfamily C is one of the most pol-
ymorphic in natural parasite isolates [4].
Although it is described that VIR proteins are immuno-
genic during natural infections, 51% of the individuals
did not present IgM or IgG antibodies to any VIR protein.
On the other hand, 70.5% of them displayed IgG antibod-
ies to recombinant proteins representing two other P.
vivax blood stage antigens (AMA-1 and MSP119), which
are extremely immunogenic during natural malaria infec-
tions and conserved in P. vivax Brazilian isolates [19,22].
The frequencies of responders found in this study is not
very different from the frequency found in an early study
performed in the endemic area of the State of Rondônia,
Brazil, using 22 different recombinant proteins, represent-
ing the various VIR subfamilies (A-E) from three patients
[4]. However, different from the present study, the recog-
nition of their recombinant proteins was analysed by
immunoblotting after protein purification by electroelu-
tion and the VIR-A was most frequently recognized by
human IgG antibodies.
Several studies with P. falciparum have demonstrated that
agglutinating antibodies from individuals living in
malaria endemic areas are known to react with the surface
of the trophozoite-infected erythrocyte [9,10,23-28]. To
date, it is believed that these agglutinating antibodies are
directed against PfEMP-1 [10,29]. It has been shown that
immunity against PfEMP-1 variants is acquired in an age-
dependent manner [10,23,24,26,27] and is associated
with protection from clinical disease [9,10]. Initial studies
suggested that immune adults might have cross-reactive
antibodies that agglutinate diverse P. falciparum isolates
[23]. However, later studies suggested that both variant-
specific and cross-reactive antibodies against PfEMP-1
might be elicited during natural infection with P. falci-
parum [30]. Very little information is available regarding
the prevalence of antibodies in individuals from endemic
areas against recombinant proteins representing specific
domains of the PfEMP-1 [31].
A second antigen belonging to the largest known family of
variable infected erythrocyte surface-expressed proteins,
the rifin proteins, is also immunogenic in natural infec-
tions. High levels of specific antibodies against recom-
binant rifin proteins were detected in the majority of the
adults living in an area of intense malaria transmission
[32,33]. Despite the high degree of diversity between rif
sequences and the high gene copy number, it appears that
P. falciparum infections can induce antibodies that cross-
react with several variant rifin molecules in many parasite
isolates in a given community, and the immune response
is most likely stable over time in a hyperendemic area
[32].
It was observed an equally distributed prevalence of IgG
subclass against each of the different recombinant pro-
teins VIR, except to VIR-C, whose antibodies are mainly
IgG1 subclass. Only a few studies have addressed the IgG
subclass distribution of VSA-specific antibody responses
in general. These studies suggested that IgG1 is the domi-
nant subclass involved in the VSA-specific IgG response in
adults [34,35]. However, two other studies indicated that
IgG3 is the dominant subclass in children [36] or that
IgG3 and IgG2 are the dominant subclasses in adults,
while in children IgG3 and IgG4 are the dominant sub-
classes [37].
Because the localities included in this study are consid-
ered as hypoendemic areas, it is not possible to establish
any correlation among antibody responses against
malaria proteins and age. To overcome this problem, an
attempt was made to determine the correlation between
antibody IgG responses to each recombinant protein VIR
and number of previous malaria episodes. In contrast to
the observations made to PfEMP-1 and rifin, this analysis,
using a significant number of sera from primary-infected
and multiple-infected individuals, showed no association
between presence of anti-VIR IgG antibodies and malaria
exposure. This data extended recent results obtained with
a smaller number of sera from individuals from Rondônia
State [4]. These results may be explained by the fact that
vir genes representing at least two different subfamilies are
transcribed concomitantly during mature stages by indi-
vidual parasites and the large repertoire of VIR proteins
found in natural parasite populations.
Also relevant is the observation that cross-reactive
epitopes between the antigens encoded by the different vir
subfamilies are undetectable after repeated infections. In
agreement with this observation, recent attempts to dem-
onstrate the cross-recognition within a subfamily and
across subfamilies by inhibition ELISA assay failed (data
not shown). It is possible that cross-reactive antibodies
that are not generated by natural infections can be elicited
by immunization with recombinant proteins. In fact, in
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ongoing studies, mice immunized with different recom-
binant proteins generated these cross-reactive antibodies
to distinct VIR subfamilies (Oliveira and Soares, unpub-
lished).
In the second part of the study, it was examined whether
VIR antigens elicited an in vitro proliferative response of
PBMC obtained from human subjects recently treated for
P. vivax infection and normal healthy individuals. PBMC
of only 14.8% of the individuals were able to proliferate
to recombinant proteins VIR and when there was a T cell
response, it was generally low in magnitude. Although the
results suggests that the PBMC response to these recom-
binant proteins is negligible in P. vivax infections, it is
impossible to rule out that they may reflect the fact that
PBMC response is more specific than antibody response
or that a larger number of individual proteins should be
surveyed.
There are no studies of T cell responses to VIR antigens to
be compared to these data. T cell responses in the field
have been described elsewhere for PfEMP-1. CD4 T cell
response to conserved regions of PfEMP-1 was signifi-
cantly greater in malaria-exposed individuals than in
unexposed Europeans, which suggests that these regions
contain peptides recognized by T cells [38,39].
Conclusion
Soluble recombinant proteins representing distinct VIR
antigens subfamilies were generated and they may be use-
ful tools to perform a number of immuno-epidemiologi-
cal studies in malaria-endemic areas. Also, this study
provides evidence that there is a low frequency of individ-
uals responding to each VIR antigen in endemic areas of
Brazil, a fact that may explain the host susceptibility to
new episodes of infection.
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